Fate Therapeutics grants employee awards: what it means for Fate Therapeutics stock

Published on 10/07/2026 at 04:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The awards covered 62,900 options and 72,700 RSUs on October 1, 2026. Fate Therapeutics stock had a EUR 2.04 prior close on October 5, 2026.

FATE, US31189P1021, Illustration mit AI erstellt.

Fate Therapeutics (ISIN US31189P1021) granted 62,900 stock options and 72,700 restricted stock units to newly hired employees on October 1, 2026, according to StockTitan. The awards are the latest disclosed corporate action for Fate Therapeutics stock and put employee incentives beside a still loss-making clinical-stage biotechnology business.

The awards mean 135,600 share units

The options cover 62,900 common shares at an exercise price of USD 2.30 per share, while the restricted stock units represent 72,700 shares, the same StockTitan report says. Together, the awards represent 135,600 shares or share units, with the options vesting over four years and 25 percent vesting after the first year.

That structure links the awards to employee retention rather than an immediate cash payment. The exercise price also sits close to the Nasdaq closing price of USD 2.30 on October 1, 2026, as stated in the company announcement carried by LD Micro.

Quarterly revenue reached USD 2.08 million

Fate Therapeutics reported USD 2.08 million of revenue in the second quarter of 2026, compared with a USD 1.94 million consensus estimate, a 7.22 percent difference, according to MarketBeat. The company posted a net loss of USD 30.16 million and diluted loss per share of USD 0.25 in that quarter.

The operating picture remains development-driven: Fate Therapeutics is building induced pluripotent stem cell-derived cellular immunotherapies for cancer and immune disorders. MarketBeat reported a consensus Hold rating from eight firms and an average price target of USD 5.90 on October 6, 2026, while the latest reported quarterly loss matched the USD 0.25 consensus loss per share.

Two conferences are scheduled for late 2026

Management plans to participate in the Jefferies Global Healthcare Conference from November 16 through November 19, 2026, and the Piper Sandler annual healthcare conference from December 1 through December 3, 2026, according to GlobeNewswire. Those dates give the market two scheduled opportunities to hear updates on the company pipeline and clinical programs.

The prior close at Lang & Schwarz was EUR 2.04 on October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of Fate Therapeutics stock.